A study to evaluate the efficacy of theracurmin (highly absorbtive curcumin) for cachexia in treatment-resistant cancer patients

The requested reference [d154890cd9bf906856d548ffd472a5fbb6559730] no longer exists in our database. It has been replaced by the current reference: [389e7887e47a2fd0ff215abe09cc2195b198ca4b]

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2014
INTERVENTION: 360mg of theracurmin per day orally for 90 days CONDITION: treatment‐resistant cancer patients PRIMARY OUTCOME: immunological effect; The expression of cytokines SECONDARY OUTCOME: At before and 30days,60days, and 90days after the administration of theracurmin; 1)Nutrition status ; 2)QOL score INCLUSION CRITERIA: 1.pathological confirmed cancer patient 2.treatment‐resistant advanced cancer patient 3.Oral intake 4.GPS. 0‐2 5.No abnormality in digestive organs due to endogenous diseases
Epistemonikos ID: 91c92e91405489d8d44e60062ff3043c2d75ecf0
First added on: Aug 22, 2024